TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00955448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIS mesh (Cook Medical)
Description: Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior prolapse repair
Description: Anterior prolapse repair will be conducted without using mesh reinforcement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior prolapse repair
Description: Anterior prolapse repair will be conducted without using mesh reinforcement
Study: NCT01386853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: 2 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 mg QD
Study: NCT03431493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation - Rehabilitation
Description: Participants will first receive a home visit from a physical therapist (PT) who will evaluate home safety and establish/verify the participant's exercise prescription. Within 1 week, an occupational therapist (OT) will visit the home to: 1) explain the purpose of behavioral activation (BA); 2) help the participant identify long-term recovery goals regarding valued activities; and 3) then, using the principles of BA, identify short-term goals for the next week and an action plan. The OT will then call the participant weekly (weeks 2-5) to review the status of the prior week's goals and use BA to set new goals for the upcoming week. The PT and OT will repeat home visits at week 6 to assess the participant's progress, and the OT will conduct phone calls every 2 weeks for weeks 8-12.
Study: NCT04371224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Liposomal Injection [Onivyde]
Description: both arm
Study: NCT03997734

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: single and repeated dosing
Study: NCT04371224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection [Onivyde]
Description: both arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: NaliCap
Study: NCT04038658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move-It
Study: NCT00372515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
Study: NCT04367454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Personal Protective Equipment
Description: As described in the arm descriptions
Study: NCT03446170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic cigarette warning labels, plain packaging
Description: This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging
Study: NCT00558493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: clevudine 30 mg qd for 24 seeks
Study: NCT03905174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: custom made device
Description: surgical intervention to place custom made orthopaedic device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: custom made device
Description: surgical intervention to place custom made orthopaedic device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: custom made device
Description: surgical intervention to place custom made orthopaedic device
Study: NCT01064284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLASMA DERIVED Factor VIII
Description: Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant FVIII
Description: Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
Study: NCT03555097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incremental pressure support
Description: Inspiratory positive airway pressure (IPAP) gradually increases from 10 to 24 cm water column (cmH2O) with 2 water column (cmH2O) increments. The expiratory positive airway pressure (EPAP) remains 4 water column (cmH2O), and each pressure level is maintained for 5 to 10 minutes.
Study: NCT06069271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kettlebell swing
Description: The intervention group completed two-handed Russian KBSs using an interval training protocol outlined by Jay et al.10 involving 30 seconds of work followed by 30 seconds of rest for 10 total intervals. Prior to completing the intervention, participants completed a general warmup consisting of 10 non-weighted squats, 10 non-weighted dead-lifts, and 10 dowel rod shoulder flexion repetitions. Participants were instructed to perform all warm-up activities at an intensity of 70% of maximal effort using a Rate of Perceived Exertion scale(RPE).
Study: NCT03406052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-Assisted MB-CBT
Description: Experimental subjects will receive a mindfulness-based CBT online software program workbook (in collaboration with Nex J Systems, Inc.) accessible online. Exposure to and interaction with the online workbook is combined with health coaching (duration of 24 total hours) primarily delivered in phone and software interactions. In addition, each participant will be given a Fitbit-HR Charge, a wearable bracelet that assesses physical steps and 24 hour heart rate in 5 second (averaged) durations (with related access to software that permits daily tracking).
Study: NCT01659541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory muscle stimulator
Description: The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
Study: NCT06740175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral optoacoustic tomography
Description: If patients are willing to participate in this study, they are imaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo) at the department of nuclear medicine and molecular imaging. The imaging procedure takes 15 minutes at most.
Study: NCT02628665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photosensitizer(photofrin)
Description: photosensitizer(photofrin): 2mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: photosensitizer(photofrin)
Description: photosensitizer(photofrin): 2mg/kg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 630 nm laser irradiation (DIOMED)
Description: 630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 630 nm laser irradiation (DIOMED)
Description: 630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
Study: NCT01954420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Intervention
Description: Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.

Intervention type: OTHER
Group type: OTHER
Intervention: Attention Control
Description: Standard care + Cancer education
Study: NCT04494022

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: contrast enhanced ultrasound
Description: Perflubutane enhanced ultrasound for evaluating hepatic tumor
Study: NCT02326545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindLight
Description: MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online CBT
Description: Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
Study: NCT04174950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing care
Description: routine perioperative nursing intervention, including intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet. NPO after the dinner one day before operation. Patients are instructed to NPO 3 days after surgery and patients should stay on the bed for 3 days. Urinary catheter is always kept for 48 hours or more.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative Enhanced Recovery After Surgery (ERAS) Based Nursing Model
Description: Establish ERAS nursing team and formulate ERAS nursing intervention. Nothing by mouth (NPO) 6 hours before operation and no water 4 hours before operation. Patients are given fluid food 24 hours after surgery. Urinary catheter is removed within 24 hours after surgery and encourage patient to mobile 24 hours after surgery. Give support to pain control and psychological support. Intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet were also given to patients.
Study: NCT01640093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate, 250 mg (uncoated, current commercial tablet)
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 500 mg (coated, reformulated tablet)
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 250 mg (coated, reformulated tablet)
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
Study: NCT01778179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tri-luma
Description: Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH.
Study: NCT04371224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: NAPOLI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: NAPOLI
Study: NCT04443998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone reducion forceps
Description: Repositioning forceps provide a more accurate anatomical reduction and higher pre-compression can be achieved compared to IMF or manual reduction
Study: NCT01247103

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD4316
Description: Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD4316
Description: Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZD4316
Study: NCT01778179

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy (CRY-AC3® device)
Description: Procedure performed at week 2.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy (CRY-AC3® device)
Description: Procedure performed at week 2.
Study: NCT02497976

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Certolizumab pegol
Description: 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT00277641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: 25 mg or 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical tablets to study drug
Study: NCT00669760

Intervention type: OTHER
Intervention: non-interventional study
Description: does not apply
Study: NCT01178996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 1000 mg (\<75 kg) or 1200 mg (\>75 kg) daily with food divided in two doses orally for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1000 mg (\<75 kg) or 1200 mg (\>75 kg) daily with food divided in two doses orally for 48 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PEGinterferon alfa2a
Description: 180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGinterferon alfa2a
Description: 180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02960997

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sirolimus, 2%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus, 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Study: NCT04526990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study: NCT03487679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Participants will undergo one day of habitual eating followed by 36 hours of water-only fasting and final day of habitual eating consuming the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
Study: NCT02382250

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Survey will be given to all participants
Study: NCT03792425

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Connective tissue graft and implant placement
Description: Augmenting soft tissue with connective tissue graft

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Connective tissue graft and implant placement
Description: Augmenting soft tissue with connective tissue graft
Study: NCT01082380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066
Study: NCT02676128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twine Collaborative Care Application
Description: This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information-Motivation-Behavioral Skills Model of ART Adherence
Description: Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
Study: NCT02511080

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spot-On
Description: use of active hot measures
Study: NCT01659541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of device
Description: The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
Study: NCT00824538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT00318708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: clarithromycin 500 mg twice daily (Biaxin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo clarithromycin
Description: placebo clarithromycin twice daily
Study: NCT04199039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect on Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction
Description: When the study started, the first 43 patients were assigned to the control group and the following 43 patients were assigned to the study group in the CVS ICU. ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted. ET fixation of the patients in the study group was performed with an ET holder (AnchorFast Oral Endotracheal Tube Fastener, Hollister, Liberlyville, USA) when they arrived at the CVS ICU.~The patients' SBP, DBP, HR and SpO2 values, which were displayed on the bedside monitor (Nihon Kohden, Tokyo), were recorded on the Hemodynamic Parameters Form just before, during, and at the end of endotracheal suction, and in the following 5th and 15th minutes.
Study: NCT03342443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
Study: NCT00702312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-salt educational programme
Description: Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-salt Bangladeshi educational programme
Description: A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-salt Bangladeshi educational programme
Description: A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
Study: NCT00542698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of Physical Activity on Type II Diabetes Mellitus
Description: Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
Study: NCT03461965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D printed model
Description: A printed 3D model of MMS will be created showing a model of skin, and a tumor to visually depict the surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal Counselling
Description: Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Counselling
Description: Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
Study: NCT01654575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 25mg/week for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once a week for 16 weeks
Study: NCT02884115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzathine penicillin
Study: NCT04786288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage with lavender essential oil mixed in a carrier oil
Description: 22 elderly participants received a one session M technique hand massage that lasted 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the M technique hand massage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: massage with odourless baby oil
Description: odourless baby oil was used for the application of one session M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.